Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?

(2021) Othman Al-Sawaf et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia

(2020) Othman Al-Sawaf et al.   BLOOD

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

(2020) Kirsten Fischer et al.   BLOOD

Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm

(2020) Annika Scheffold et al.   Current Oncology Reports

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

(2020) Eugen Tausch et al.   BLOOD

Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm

(2020) Manju Sengar et al.   Current Hematologic Malignancy Reports

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

(2020) Arnon P. Kater et al.   JOURNAL OF CLINICAL ONCOLOGY

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

(2019) Peter Hillmen et al.   JOURNAL OF CLINICAL ONCOLOGY

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

(2019) Kirsten Fischer et al.   NEW ENGLAND JOURNAL OF MEDICINE

The evolving treatment landscape of chronic lymphocytic leukemia

(2019) Luana Schiattone et al.   CURRENT OPINION IN ONCOLOGY

Practical management of tumour lysis syndrome in venetoclax‐treated patients with chronic lymphocytic leukaemia

(2019) John G. Gribben   BRITISH JOURNAL OF HAEMATOLOGY

Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands

(2018) Sabina Kersting et al.   Clinical Lymphoma Myeloma & Leukemia

Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy

(2018) Jan A. Burger et al.   Nature Reviews Clinical Oncology

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

(2018) John F. Seymour et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

(2018) Arnon P. Kater et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group

(2016) Gabor Kovacs et al.   JOURNAL OF CLINICAL ONCOLOGY

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

(2015) A C Rawstron et al.   LEUKEMIA

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

(2012) Sebastian Böttcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

(2009) S Böttcher et al.   LEUKEMIA

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD